$ARTV News

Last published 2w ago

2w agoARTVArtiva Biotherapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 2.05 Item 9.01
2w agoARTVArtiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®GlobeNewswireCompany halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trialUpdated deep B cell depletion and clinical response data is consistent with previously reported findings; however,
1mo agoARTVARTIVA BIOTHERAPEUTICS, INC. STIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - ARTIVA BIOTHERAPEUTICS INCEarnings Call TranscriptsHey, everyone. We are back. Our next Fireside Chat is with Fred Osland, CEO of Artiva Therapeutics. Maybe I'll kick it over to Fred for a quick overview of the company, and then we'll get into a Q&A. So, Fred, over to yo
1mo agoARTVArtiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumGlobeNewswireSAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for
2mo agoARTVArtiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026GlobeNewswireUpdated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial,
2mo agoARTVArtiva Biotherapeutics to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireSAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for
3mo agoARTVArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireClinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient
3mo agoARTVArtiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients
4mo agoARTVArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobeNewswireSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients
5mo agoARTVArtiva Biotherapeutics Post-EULAR Virtual Webcast - ARTIVA BIOTHERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for joining us today for ARTIVA Biotherapeutics webcast and conference call on data presented at the ULAR 2026 Congress. I'm Nipur Lifik, Strategic Investor Relations Advisor for A
5mo agoARTVArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodayGlobeNewswireMultiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosisLate-breaking oral
5mo agoARTVJeffries Global Healthcare Conference in New York - ARTIVA BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning everyone. Welcome to day two of Jeffries Global Healthcare Conference. My name is Fiona Jha. I cover SMECAP biotech companies at Jeffries. And it is my great pleasure to welcome to the stage Arteva Biotherap
5mo agoGTBP IBRX FATE NKTX+1The $13 Million Company Teaching the Immune System to Hunt CancerPR NewswireUSA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)...
5mo agoARTVArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireSAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with
5mo agoARTVArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic DiseasesGlobeNewswireLate-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory
5mo agoARTVArtiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and DevelopmentGlobeNewswireVeteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from
6mo agoGTBP ARTV FATE IBRX+1Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhasePR NewswireMomentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across...
6mo agoARTVArtiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for
6mo agoARTVArtiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireInitial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no
6mo agoARTVArtiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026GlobeNewswireInitial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or
7mo agoARTVArtiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients
8mo agoARTVArtiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswireInitial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for
8mo agoARTVArtiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireSAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients
8mo agoARTVArtiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement GrantGlobeNewswireSAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for
8mo agoARTVArtiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of DirectorsGlobeNewswireSAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for
9mo agoARTVArtiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHLGlobeNewswireSAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for
10mo agoARTVSeasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicinesPR NewswireNanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics,...
12mo agoARTVArtiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune DiseaseGlobeNewswire32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community
12mo agoARTVArtiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireOver 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, the first known
1y agoARTVArtiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®GlobeNewswireThe virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a
1y agoARTVArtiva Biotherapeutics to Participate in Upcoming Investor Conferences in NovemberGlobeNewswireSAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
1y agoARTVArtiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate UpdateGlobeNewswirePrioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep
1y agoARTVArtiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025GlobeNewswireSAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
1y agoARTVArtiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business HighlightsGlobeNewswireFirst patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis
1y agoARTV CTNMArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board ChairBusiness WireArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery,
1y agoARTVArtiva Biotherapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireSAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
1y agoARTVArtiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingGlobeNewswire64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of
1y agoARTVArtiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business HighlightsGlobeNewswireIND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to
1y agoARTVArtiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingGlobeNewswireProlonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional
1y agoARTVArtiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerGlobeNewswireSAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
1y agoARTVArtiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
1y agoARTVArtiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswireInitial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical
1y agoARTVArtiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireSAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
1y agoARTVArtiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.GlobeNewswireSAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
1y agoARTVArtiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswireExpanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications
2y agoARTVArtiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
2y agoALLO ARTV CDXSArtiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsGlobeNewswireSAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
2y agoARTVArtiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients
2y agoARTVArtiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswireStrong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple
2y agoARTVArtiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public OfferingGlobeNewswireSAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients